stockrow
Friday 6 November 2026
Export MOBI’s income statement to Excel — free account
Mobia Medical, Inc
MOBI Healthcare Medical Devices
Mobia Medical, Inc’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 104.8% from fiscal 2024.
- Revenue
- +175.9%
- EPS
- +96.0%
- Free cash flow
- −18.0%
Quarter to September 2026, against a year earlier
10.97
0.31
−2.75%
Follow MOBI
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(10.64) | (19.74) |
P/FCF ratio |
0.00 | 0.00 |
Beneish M-Score |
(1.68) | — |
P/Operating CF |
(0.61) | (0.61) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(0.04) | (0.04) |
EV/FCF |
(0.04) | (0.04) |
Quick Ratio |
3.73 | 3.80 |
Current Ratio |
4.54 | 4.61 |
Net Debt/EBITDA |
0.57 | 0.31 |
Debt/Assets |
14.81% | 32.11% |
Debt/Equity |
0.25 | (0.07) |
Asset Turnover |
0.91 | 0.00 |
Operating CF/Net income |
0.98 | 0.99 |
Capex/Depreciation |
(1.94) | (0.27) |
Interest Coverage |
(47.93) | (24.99) |
| 36.21% | 0.00% | |
| (132.40%) | 0.00% | |
ROIC |
(1,140.09%) | 0.00% |
Return on Tangible Assets |
(126.28%) | (144.43%) |
Average Days of Receivables |
50.52 | 65.94 |
Research and Development Expense of Revenue |
20.33% | 27.12% |
Selling, General and Administrative Expense of Revenue |
205.45% | 207.38% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
4.52% | 4.85% |
Graham Net Nets |
0.94 | 0.94 |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(341.88%) | (341.88%) |
Free Cash Flow Yield |
(783.22%) | (783.22%) |
Revenue per Share |
37.74 | 27.21 |
Operating CF per Share |
(53.82) | (42.29) |
Capex per Share |
(0.43) | (0.07) |
Free Cash Flow per Share |
(54.25) | (42.36) |
Cash per Share |
39.56 | 25.43 |
Shareholders Equity per Share |
34.16 | (184.41) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
34.16 | (184.41) |
Free Cash Flow |
(46.06) | (24.36) |
Working Capital |
36.15 | 16.58 |
Capital Expenditures |
(0.36) | (0.04) |
Net Current Asset Value |
27.21 | (106.95) |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.28 | 0.33 |
Cash ROIC |
(66.07%) | 28.88% |
Accounts Receivable Turnover |
8.83 | 0.00 |
Accounts Payable Turnover |
3.61 | 0.00 |
Inventory Turnover |
1.37 | 0.00 |
Average Days of Payables |
133.76 | 130.23 |
Days of Inventory on Hand |
328.34 | 391.98 |
Average Receivables |
3.63 | — |
Average Payables |
1.68 | — |
Average Inventory |
4.44 | — |
Average Assets |
35.12 | — |
Average Common Equity |
(128.40) | — |
Columns are period end dates · fundamentals updated 5 Nov 2026